Bank Julius Baer & Co
CLRB icon

Bank Julius Baer & Co’s Cellectar Biosciences CLRB Stock Holding History

Bank Julius Baer & Co’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25
Closed -$9K – 813
2021
Q2 		$9K Hold
25
– – ﹤0.01% 784
2021
Q1 		$12K Buy
+25
New +$14.9K ﹤0.01% 771

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank Julius Baer & Co's CLRB Position: Q3 2021 in Review

Bank Julius Baer & Co sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 25 shares — an estimated $9K sold.

Bank Julius Baer & Co first reported a position in CLRB in Q1 2021 and held it in 2 quarters. The position peaked at $12K in Q1 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • Bank Julius Baer & Co reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 25 Cellectar Biosciences shares in Q3 2021, an estimated $9K.
  • Bank Julius Baer & Co first reported a position in Cellectar Biosciences in Q1 2021 and held it in 2 quarters.
  • Bank Julius Baer & Co's Cellectar Biosciences position peaked at $12K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on Bank Julius Baer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.